Fig. 4: R54 increased pAKT in PB-RCC Tregs.
From: Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients
a AKT phosphorylation (pAKT) in CD4+Foxp3+ Tregs in PB-RCC patients and HDs. PBMCs were treated with R54 (10 µM) for 30’, washed and stimulated with IL-2 (100 nM)/PMA (40 nM) for 15’ (RCC: CTR 15 ± 3% vs. IL2/PMA 6 ± 1%; p < 0.05; IL2/PMA 6 ± 1% vs. IL2/PMA + R54 14 ± 3%; p < 0.05). The box plot represents the median and spread of data within min to max value (RCC, n = 13; HD, n = 10). In the lower panel, representative density plots were shown. b pAKT in isolated PB-RCC-Tregs and HDs in the presence of AKT inhibitors. Tregs were treated for 16 h with AKT inhibitor-(TCB) (20 µM) and then with R54 (10 µM) for 30’, washed and stimulated with IL-2 (100 nM)/PMA (40 nM) for 15’ (RCC: Treg-IL2/PMA + R54 25 ± 2% vs. Treg-IL2/PMA + R54 + TCB 14 ± 2%, p < 0.01). The box plot represents the median and spread of data within min to max value (RCC, n = 8; HD, n = 6). Paired and unpaired Student’s t-test was used. (*p < 0.05; **p < 0.01; ***p < 0.001). Data are derived from at least three independent experiments.
